EUVIMEDScopri EUVIMED
Crossref

Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma

Lin Shi iD, Dianliang Lv, Xueying Wang iD, Kuanshun Zhang, Lei Feng, Runfang Zhang, Jiangshan Zhao

Chemical Biology & Drug Design · 2026-04 · 107 (4)

DOI: 10.1111/cbdd.70284 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-04-13. Written by Lin Shi and 6 co-authors. Institution: Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional …. Major MEDLINE topics: Multiple Myeloma, Bortezomib, HSP90 Heat-Shock Proteins, Ferroptosis. Cited 1 times so far (Crossref); 31 references. Funded by: Specialized Research Topics of Henan Pronincial Scientific Research in Traditional Chinese Medicine.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Multiple myeloma (MM) is a hematologic malignancy commonly treated with bortezomib (BTZ). However, treatment efficacy is often limited by the development of BTZ resistance. Icaritin has demonstrated broad anti‐tumor activities. This study aimed to investigate the effect of Icaritin on the malignant progression of MM and its potential to overcome BTZ resistance. The anti‐MM activity of Icaritin was evaluated through a series of experimental approaches, including cell counting kit 8, flow cytometry, 5‐ethynyl‐2′‐deoxyuridine, network pharmacology, molecule docking, reverse transcription‐quantitative polymerase chain reaction, Co‐Immunoprecipitation (CoIP), and western blot. Icaritin suppressed MM cell viability and proliferation, induced ferroptosis, and enhanced cellular sensitivity to BTZ. Moreover, Icaritin inhibited HSP90α family 1 (HSP90AA1) protein expression via promoting ubiquitination. HSP90AA1 facilitated MM cell proliferation, suppressed ferroptosis, and attenuated BTZ sensitivity. Notably, Icaritin promoted MM cell ferroptosis and BTZ sensitivity by inhibiting HSP90AA1. In vivo, Icaritin enhanced the sensitivity of tumor cells to BTZ. Icaritin suppresses malignant progression, induces ferroptosis, and enhances BTZ sensitivity in MM by inhibiting HSP90AA1. These findings provide a novel theoretical basis for Icaritin treatment of MM and regulation of BTZ sensitivity.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaBortezomibHSP90 Heat-Shock ProteinsFerroptosisFlavonoidsAntineoplastic AgentsHumansCell Line, TumorAnimalsCell ProliferationCell SurvivalMice

Author keywords

HSP90AA1Icaritinbortezomibferroptosismultiple myeloma

Substances

icaritinBortezomibHSP90 Heat-Shock ProteinsFlavonoidsAntineoplastic Agents

Authors and institutions

  • Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Institute of Hematology, Henan University of Tradit…
  • The Second Clinical Medical School, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China.

ORCID profiles: Lin Shi, Xueying Wang

Funding

  • Specialized Research Topics of Henan Pronincial Scientific Research in Traditional Chinese Medicine

Cite

APA

Shi, L., Lv, D., Wang, X., Zhang, K., Feng, L., Zhang, R., & Zhao, J. (2026). Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma. Chemical Biology & Drug Design, 107(4). https://doi.org/10.1111/cbdd.70284

Vancouver

Shi L, Lv D, Wang X, Zhang K, Feng L, Zhang R, et al. Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma. Chemical Biology & Drug Design. 2026;107(4). doi:10.1111/cbdd.70284

BibTeX
@article{Shi2026,
  author = {Shi, Lin and Lv, Dianliang and Wang, Xueying and Zhang, Kuanshun and Feng, Lei and Zhang, Runfang and Zhao, Jiangshan},
  title = {Icaritin Inhibits Malignant Progression and Enhances Ferroptosis and Bortezomib Sensitivity by Suppressing HSP90AA1 Expression in Multiple Myeloma},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {4},
  doi = {10.1111/cbdd.70284}
}
Start for free →